Technical Analysis for RCKT - Rocket Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Flat | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.29% | |
Gapped Up | Strength | -1.29% | |
Up 3 Days in a Row | Strength | -1.29% | |
Upper Bollinger Band Touch | Strength | -1.29% | |
Shooting Star Candlestick | Bearish | -0.11% | |
Lizard Bearish | Bearish Day Trade Setup | -0.11% | |
Crossed Above 200 DMA | Bullish | -0.11% | |
Doji - Bearish? | Reversal | -0.11% | |
Gapped Up | Strength | -0.11% | |
200 DMA Resistance | Bearish | 1.15% |
Alert | Time |
---|---|
Fell Below 200 DMA | 19 minutes ago |
200 DMA Support | about 2 hours ago |
Down 1% | about 2 hours ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | about 2 hours ago |
Fell Below Previous Day's Low | about 2 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Rocket Pharmaceuticals, Inc. Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immune System Bone Heart Failure Anemia Bone Marrow Cancer Research Blood Cells Red Blood Cell Genetic Disorder Petros Fanconi Anemia Pyruvate Kinase Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.53 |
52 Week Low | 14.89 |
Average Volume | 671,451 |
200-Day Moving Average | 23.37 |
50-Day Moving Average | 24.93 |
20-Day Moving Average | 22.97 |
10-Day Moving Average | 23.20 |
Average True Range | 1.03 |
RSI (14) | 50.00 |
ADX | 14.49 |
+DI | 23.73 |
-DI | 18.22 |
Chandelier Exit (Long, 3 ATRs) | 21.68 |
Chandelier Exit (Short, 3 ATRs) | 24.52 |
Upper Bollinger Bands | 24.29 |
Lower Bollinger Band | 21.65 |
Percent B (%b) | 0.76 |
BandWidth | 11.46 |
MACD Line | -0.44 |
MACD Signal Line | -0.67 |
MACD Histogram | 0.2369 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.06 | ||||
Resistance 3 (R3) | 25.17 | 24.81 | 24.82 | ||
Resistance 2 (R2) | 24.81 | 24.46 | 24.76 | 24.74 | |
Resistance 1 (R1) | 24.24 | 24.24 | 24.06 | 24.13 | 24.67 |
Pivot Point | 23.88 | 23.88 | 23.80 | 23.83 | 23.88 |
Support 1 (S1) | 23.31 | 23.53 | 23.13 | 23.20 | 22.65 |
Support 2 (S2) | 22.95 | 23.31 | 22.90 | 22.58 | |
Support 3 (S3) | 22.38 | 22.95 | 22.50 | ||
Support 4 (S4) | 22.27 |